I hate to break it to you, but it will be substantially more difficult to target other organ systems. The liver is uniquely easy to target with our current vect

I hate to break it to you, but it will be substantially more difficult to target other organ systems. The liver is uniquely easy to target with our current vectors. Right off the bat, the liver receives roughly a quarter of all cardiac output, either directly or second hand from the digestive organs. Additionally, the liver has a fenestrated endothelium which, while not completely unique in the body, uniquely allows molecules like lipid nanoparticles (LNPs) to access liver cells. Finally, the liver is the site of most lipoprotein processing, and LNPs can be designed to take advantage of the existing pathways to get the gene editing mRNA into the hepatocytes. All this is to say that if you have a genetic condition that primarily effects the liver, there's a lot more hope for treatment in the near term than for others. Good lecture on the difficulties of finding appropriate platforms for delivering gene therapies to cells for anyone interested [1] [1] https://youtu.be/6URTjoK58Yc https://youtu.be/6URTjoK58Yc